Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rugocrixan - Novakand Pharma

Next Previous
Drug Profile

Rugocrixan - Novakand Pharma

Alternative Names: AZD-8797; KAN-0440567; KAND-567

Latest Information Update: 06 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Novakand Pharma
  • Class 2 ring heterocyclic compounds; Amines; Analgesics; Anti-inflammatories; Antineoplastics; Cardiovascular therapies; Neuroprotectants; Organic sulfur compounds; Pyrimidines; Small molecules; Thiazoles
  • Mechanism of Action Chemokine CXCL13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fallopian tube cancer; Myocardial infarction; Ovarian cancer; Peritoneal cancer; SARS-CoV-2 acute respiratory disease
  • No development reported Autoimmune disorders; Breast cancer; Cancer pain; Cardiovascular disorders; Spinal cord injuries
  • Discontinued Multiple myeloma

Most Recent Events

  • 22 Sep 2025 Kancera is now called Novakand Pharma
  • 29 Aug 2025 Updated pharmacodynamics and adverse event data from the phase II FRACTAL study in Mycadial infarction presented at the Annual Congress of the European Society of Cardiology together with World Congress of Cardiology (ESC-Card-WCC-2025)
  • 13 Jun 2025 Adverse events and efficacy data from a phase I/II KANDOVA trial in Fallopian tube cancer, Ovarian cancer, Peritoneal cancer released by Kancera

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top